[
  {
    "ts": null,
    "headline": "Regeneron Announces Investor Conference Presentations",
    "summary": "TARRYTOWN, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: BofA Securities 2025 Health Care Conference at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, May 13, 20252025 RBC Capital Markets Global Healthcare Conference at 11:00 a.m. ET on Tuesday, May 20, 2025Bernstein 41st Annual Strategic Decisions Conference at 11:00 a.m. ET on Wednesday, May 28, 2025Goldman Sachs 46th Annual Global Healthcare Conference at 10",
    "url": "https://finnhub.io/api/news?id=18e59a94b237844c20cd320fadb45e5100024899b42a38adeda781f83eb8b4c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745265900,
      "headline": "Regeneron Announces Investor Conference Presentations",
      "id": 134026552,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "TARRYTOWN, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: BofA Securities 2025 Health Care Conference at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, May 13, 20252025 RBC Capital Markets Global Healthcare Conference at 11:00 a.m. ET on Tuesday, May 20, 2025Bernstein 41st Annual Strategic Decisions Conference at 11:00 a.m. ET on Wednesday, May 28, 2025Goldman Sachs 46th Annual Global Healthcare Conference at 10",
      "url": "https://finnhub.io/api/news?id=18e59a94b237844c20cd320fadb45e5100024899b42a38adeda781f83eb8b4c0"
    }
  },
  {
    "ts": null,
    "headline": "Transcript : Regeneron Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10",
    "summary": "Presenter SpeechTimothy Anderson [Audio Gap] conference with BofA in Vegas and also excited to have Regeneron with us. Two speakers, Marion McCourt, who is Executive Vice President and Head of...",
    "url": "https://finnhub.io/api/news?id=616e20c76397894286aec01b13a6f5be42f890766feddd211cb728f35c2b3d5f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745251500,
      "headline": "Transcript : Regeneron Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10",
      "id": 134402877,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Presenter SpeechTimothy Anderson [Audio Gap] conference with BofA in Vegas and also excited to have Regeneron with us. Two speakers, Marion McCourt, who is Executive Vice President and Head of...",
      "url": "https://finnhub.io/api/news?id=616e20c76397894286aec01b13a6f5be42f890766feddd211cb728f35c2b3d5f"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron's FDA Setback on Eylea HD Dosing 'No Biggie,' Says Oppenheimer",
    "summary": "The US Food and Drug Administration's rejection of Regeneron Pharmaceuticals' (REGN) bid to extend t",
    "url": "https://finnhub.io/api/news?id=4c51e133f272d31345c8e1876ed8cf0429cf3c3606ef33eaf497805a2af4867b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745246537,
      "headline": "Regeneron's FDA Setback on Eylea HD Dosing 'No Biggie,' Says Oppenheimer",
      "id": 134023039,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The US Food and Drug Administration's rejection of Regeneron Pharmaceuticals' (REGN) bid to extend t",
      "url": "https://finnhub.io/api/news?id=4c51e133f272d31345c8e1876ed8cf0429cf3c3606ef33eaf497805a2af4867b"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria",
    "summary": "The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.",
    "url": "https://finnhub.io/api/news?id=806d9af799bcb20db1cf8912e35625cae33a952496b0b145acaf772992573000",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745241720,
      "headline": "Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria",
      "id": 134023040,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.",
      "url": "https://finnhub.io/api/news?id=806d9af799bcb20db1cf8912e35625cae33a952496b0b145acaf772992573000"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi and Regeneron’s dupilumab approved by FDA for urticaria",
    "summary": "The decision is supported by data from the Phase III Study A and Study C clinical trials.",
    "url": "https://finnhub.io/api/news?id=00786662282ca1f68394f4bc7c68e3a8b15a335f577ef6e62d93ba3ef1c1703c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745226636,
      "headline": "Sanofi and Regeneron’s dupilumab approved by FDA for urticaria",
      "id": 134023041,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The decision is supported by data from the Phase III Study A and Study C clinical trials.",
      "url": "https://finnhub.io/api/news?id=00786662282ca1f68394f4bc7c68e3a8b15a335f577ef6e62d93ba3ef1c1703c"
    }
  }
]